ERBB2 and breast cancer: This observed effect persisted consistently across all BC subtypes (HR+ BC 29 vs. 9 months; HER2+ BC 24 vs. 12 months; TN 12 vs. 6 months; p < 0.05; log-rank test; Supplementary Table 2; Fig. 3b–d) and throughout the three decades (1992–1999: 14 vs. 9 months; 2000–2009: 19 vs. 8 months; 2010–2020: 27 vs. 9 months; p < 0.05; log-rank test, Supplementary Table 4).